Marine sponge derived eribulin in preclinical and clinical studies for cancer

Umang Swami, Umang Shah, Sanjay Goel

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Eribulin mesylate is a completely synthetic, structurally simplified, macrocyclic ketone analogue of Halichondrin B. Halichondrin B is complex, natural, macrocyclic polyether derived from marine sponges. Eribulin has been approved by United States Food and Drug Administration in 2010 as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has a microtubule dynamics inhibitory action. Preclinical studies have demonstrated a broad spectrum of anti-tumor activity in various cancer cell lines and synergistic action with multiple anticancer agents. It has also undergone clinical trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Various combination trials are currently ongoing. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies and clinical trials.

Original languageEnglish (US)
Title of host publicationHandbook of Anticancer Drugs from Marine Origin
PublisherSpringer International Publishing
Pages59-100
Number of pages42
ISBN (Print)9783319071459, 9783319071442
DOIs
StatePublished - Jan 1 2015

Fingerprint

eribulin
Porifera
pharmacology
sponge
clinical trials
cancer
anthracyclines
taxanes
pancreatic neoplasms
neutropenia
neoplasms
Tumors
antineoplastic agents
Prostatic Neoplasms
sarcoma
prostatic neoplasms
lung neoplasms
ketones
Cells
Clinical Trials

Keywords

  • Breast cancer
  • E7389
  • Embrace
  • Eribulin
  • Halaven™
  • Halichondrin B
  • Microtubule inhibitor
  • Nsc 707389

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Agricultural and Biological Sciences(all)
  • Environmental Science(all)

Cite this

Swami, U., Shah, U., & Goel, S. (2015). Marine sponge derived eribulin in preclinical and clinical studies for cancer. In Handbook of Anticancer Drugs from Marine Origin (pp. 59-100). Springer International Publishing. https://doi.org/10.1007/978-3-319-07145-9_4

Marine sponge derived eribulin in preclinical and clinical studies for cancer. / Swami, Umang; Shah, Umang; Goel, Sanjay.

Handbook of Anticancer Drugs from Marine Origin. Springer International Publishing, 2015. p. 59-100.

Research output: Chapter in Book/Report/Conference proceedingChapter

Swami, U, Shah, U & Goel, S 2015, Marine sponge derived eribulin in preclinical and clinical studies for cancer. in Handbook of Anticancer Drugs from Marine Origin. Springer International Publishing, pp. 59-100. https://doi.org/10.1007/978-3-319-07145-9_4
Swami U, Shah U, Goel S. Marine sponge derived eribulin in preclinical and clinical studies for cancer. In Handbook of Anticancer Drugs from Marine Origin. Springer International Publishing. 2015. p. 59-100 https://doi.org/10.1007/978-3-319-07145-9_4
Swami, Umang ; Shah, Umang ; Goel, Sanjay. / Marine sponge derived eribulin in preclinical and clinical studies for cancer. Handbook of Anticancer Drugs from Marine Origin. Springer International Publishing, 2015. pp. 59-100
@inbook{a310f99ecdca4a3b8ac228b467620955,
title = "Marine sponge derived eribulin in preclinical and clinical studies for cancer",
abstract = "Eribulin mesylate is a completely synthetic, structurally simplified, macrocyclic ketone analogue of Halichondrin B. Halichondrin B is complex, natural, macrocyclic polyether derived from marine sponges. Eribulin has been approved by United States Food and Drug Administration in 2010 as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has a microtubule dynamics inhibitory action. Preclinical studies have demonstrated a broad spectrum of anti-tumor activity in various cancer cell lines and synergistic action with multiple anticancer agents. It has also undergone clinical trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Various combination trials are currently ongoing. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies and clinical trials.",
keywords = "Breast cancer, E7389, Embrace, Eribulin, Halaven™, Halichondrin B, Microtubule inhibitor, Nsc 707389",
author = "Umang Swami and Umang Shah and Sanjay Goel",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-07145-9_4",
language = "English (US)",
isbn = "9783319071459",
pages = "59--100",
booktitle = "Handbook of Anticancer Drugs from Marine Origin",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Marine sponge derived eribulin in preclinical and clinical studies for cancer

AU - Swami, Umang

AU - Shah, Umang

AU - Goel, Sanjay

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Eribulin mesylate is a completely synthetic, structurally simplified, macrocyclic ketone analogue of Halichondrin B. Halichondrin B is complex, natural, macrocyclic polyether derived from marine sponges. Eribulin has been approved by United States Food and Drug Administration in 2010 as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has a microtubule dynamics inhibitory action. Preclinical studies have demonstrated a broad spectrum of anti-tumor activity in various cancer cell lines and synergistic action with multiple anticancer agents. It has also undergone clinical trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Various combination trials are currently ongoing. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies and clinical trials.

AB - Eribulin mesylate is a completely synthetic, structurally simplified, macrocyclic ketone analogue of Halichondrin B. Halichondrin B is complex, natural, macrocyclic polyether derived from marine sponges. Eribulin has been approved by United States Food and Drug Administration in 2010 as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has a microtubule dynamics inhibitory action. Preclinical studies have demonstrated a broad spectrum of anti-tumor activity in various cancer cell lines and synergistic action with multiple anticancer agents. It has also undergone clinical trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Various combination trials are currently ongoing. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies and clinical trials.

KW - Breast cancer

KW - E7389

KW - Embrace

KW - Eribulin

KW - Halaven™

KW - Halichondrin B

KW - Microtubule inhibitor

KW - Nsc 707389

UR - http://www.scopus.com/inward/record.url?scp=84940412442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940412442&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-07145-9_4

DO - 10.1007/978-3-319-07145-9_4

M3 - Chapter

SN - 9783319071459

SN - 9783319071442

SP - 59

EP - 100

BT - Handbook of Anticancer Drugs from Marine Origin

PB - Springer International Publishing

ER -